NFMRI Australia Alzheimer’s Funding Call

NFMRI seeks to support the translation of biomedical research projects that have strong potential in addressing unmet community needs. Funding provided by NFMRI is very different from other foundations and traditional funding sources, which is why we recommend that applicants read more about the Foundation prior to submitting an expression of interest.

Around the beginning of each calendar year, NFMRI opens its general grant round nationally, which seeks to support innovative biomedical research projects covering all diseases and conditions. From time to time, via our partnerships, we may offer targeted funding rounds based around our partners’ mission and objectives. The best way to keep informed of these special purpose funding rounds is to subscribe up to our newsletter.

NFMRI recognises the valuable time researchers and reviewers spend preparing and assessing applications for support. To assist in managing this valuable resource, we ask that all applicants firstly complete and submit an expression of interest form (EOI). Shortlisted applicants will then be invited to submit a more detailed application relevant to the portfolio selected in their EOI. Prior to completing the EOI, all applicants should read and understand the information relating to the support provided by the Foundation. Particularly, applicants should review their application’s strategic fit with the mission of the Foundation, the three research portfolios and consider how their research advances innovation, noting any nominated areas of priority.

Funding is available to support Australian research projects investigating potential causes, treatments and/or a cure for Alzheimer’s disease.

Through our partnership with The Mason Foundation (managed by Equity Trustees), NFMRI will continuously be accepting expressions of interest for research into Alzheimer’s disease, subject to available funds. Expressions of interest may be submitted at any time and will be reviewed in line with the next cut-off date once received. All three portfolios are open, with preference for projects that fall within portfolios 2 and 3. A key aspect of portfolios 2 and 3 is accessing external capability to undertake critical research with high translational value.

We strongly encourage women to apply and for the researcher leading the project day-to-day to be listed as the chief investigator, including mid-career researchers. The focus of our reviews will be on the innovation and its potential of successfully securing the relevant next-step partner.

The next cut-off dates for Alzheimer’s disease EOIs include:

  • 6pm AEST, 14 October 2021 – Funding announcements expected to be made in August 2022.
  • 6pm AEST, 21 March 2022 – Funding announcements expected to be made in November 2022.

Further cut-off dates may be announced in the future subject to available funding.


The EOI form can be downloaded by clicking here

Visit funding web page

Translate »